NCT07349472 Pentoxifylline in Patients With Ulcerative Colitis
| NCT ID | NCT07349472 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Ihab Elsayed Hassan |
| Condition | Inflammatory Bowel Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2027-01-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 60 participants in total. It began in 2026-01-20 with a primary completion date of 2027-01-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Both male and female will be included * Negative pregnancy test and effective contraception. * Mild and moderate UC patients Exclusion Criteria: * Breast feeding * Significant liver and kidney function abnormalities * Diabetic patients * Colorectal cancer patients * Patients with severe UC * Patients taking rectal or systemic steroids * Patients taking immunosuppressives or biological therapies * Addiction to alcohol and / or drugs * Known allergy to the studied medications
Frequently Asked Questions
Who can join the NCT07349472 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Inflammatory Bowel Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07349472 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07349472 currently recruiting?
Yes, NCT07349472 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ihab Elsayed Hassan to inquire about joining.
Where is the NCT07349472 trial being conducted?
This trial is being conducted at Al Fayyum, Egypt.
Who is sponsoring the NCT07349472 clinical trial?
NCT07349472 is sponsored by Ihab Elsayed Hassan. The trial plans to enroll 60 participants.